Analog comparison
Put a native hormone next to the analogs engineered from it — or compare any molecules in the catalog. The same receptor, a different half-life: see how protease resistance and acylation stretch a peptide’s duration from minutes to days while the underlying mechanism stays the same.
| Type | Endogenous | Analog |
|---|---|---|
| Evidence | Established | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Incretin peptide (42 aa) | Dual GIP/GLP-1 receptor agonist (39 aa, acylated) |
| Receptor | GIP receptor (GIPR), a class B GPCR | GIP receptor + GLP-1 receptor |
| Molecular weight | ~4,983.6 Da | ~4,813.5 Da |
| Half-life | ||
| Based on | Native hormone | Glucose-dependent insulinotropic polypeptide |
Half-life bars are on a logarithmic scale across the molecules shown, so a minutes-long native peptide and a once-weekly analog stay legible together. Reference values for the native or representative form — educational only, not medical or dosing advice.
How to read a lineage
Most engineered peptides are not new mechanisms — they are durability solutions. An analog usually binds the same receptor as its native hormone; what changes is how long it survives in circulation. Native GLP-1 is cleared by DPP-4 in a minute or two, while its acylated analogs bind albumin and persist for days.
Reading left to right along a lineage, watch three columns: receptor (often identical — the mechanism is conserved), molecular weight (analogs are deliberately larger, carrying fatty-acid chains), and half-life (the payoff — the engineering target).
Want the dosing consequences of those half-lives? Each molecule links straight into the half-life & dosing calculator.
Reference-grade approximations for the native or representative form of each molecule. Engineered formulations (depots, extended-release) differ substantially. Educational only — not medical advice, dosing guidance, or a recommendation to use any substance.